Publication: Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia
0
0
Issued Date
2010
Resource Type
File Type
application/pdf
ISSN
87563282
Other identifier(s)
2-s2.0-77950532155
Rights Holder(s)
Scopus
Bibliographic Citation
Bone. Vol 46, No.4 (2010), p.1011-1015
Suggested Citation
Chuengsamarn S., Rattanamongkoulgul S., Suwanwalaikorn S., Wattanasirichaigoon S., Kaufman L. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone. Vol 46, No.4 (2010), p.1011-1015. doi:10.1016/j.bone.2009.12.023 Retrieved from: https://hdl.handle.net/20.500.14740/7595
Abstract
Introduction: The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, named statins, are well-established cholesterol-lowering drugs able to reduce cardiovascular risk in hypercholesterolemic patients. The possible effect of statin on bone tissue, so-called pleiotropic effects has received particular attention. Studies reported a positive effect of statin on bone tissue in both of animal and human study by enhancing the expression of the bone morphogenetic proteins (BMPs), in particular of BMP2, which in turn leads to osteoblast differentiation and bone formation including interfering with osteoclastic activity. In a systematic review, the lipophilic statin as simvastatin had positive effect to bone mineral density (BMD) better than the more hydrophilic statin such as atorvastatin and fluvastatin. This study was aimed to compare efficacy of medical therapy between HMG-CoA reductase inhibitor and non-HMG-CoA reductase inhibitor group to changing of bone mineral density and bone markers in the patients with hyperlipidemia. Materials and methods: A prospective randomized control trial study enrolled the 212 hyperlipidemia with osteopenia patients to study in year 2006-2008. All subjects were randomized to 2 groups between statin and non-statin group; the patients were screened by inclusion criteria and measured in bone mineral density (BMD), bone marker and blood chemistry. All data were analyzed by difference of changing in bone marker and BMD between statin and non-statin groups using paired t test. Results: The present study showed 212 hyperlipidemia with osteopenia patients of which 106 patients in statin group had mean age (63.17±9.51 years) and the same number of patients in non-statin group had mean age (60.96±8.9 years). All subjects were 63 patients in male and 149 patients in female. Difference of bone formation marker and BMD between after and before was significantly higher than in statin group and the difference of bone resorption marker was also significantly lower than in statin group. Conclusion: The lipophilic statin as moderate to high dose of simvastatin had beneficial positive effect to increasing BMD and could be additive use for prevention of bone loss in hyperlipidemia patients. © 2010 Elsevier Inc.
Subject(s)
Amino terminal telopeptide
Bone morphogenetic protein 2
Carboxy terminal telopeptide
Cholesterol
Fibric acid derivative
Gemfibrozil
High density lipoprotein cholesterol
Hydroxymethylglutaryl coenzyme A reductase inhibitor
Lipid
Low density lipoprotein cholesterol
Simvastatin
Triacylglycerol
Adult
Aged
Article
Blood analysis
Blood sampling
Bone density
Bone tissue
Cell differentiation
Clinical trial
Controlled clinical trial
Controlled study
Diet restriction
Drug dose increase
Female
Human
Hyperlipidemia
Lipophilicity
Major clinical study
Male
Ossification
Osteoblast
Osteoclast
Osteolysis
Osteopenia
Osteoporosis
Pleiotropy
Protein expression
Randomized controlled trial
Treatment outcome
Aged
Antilipemic Agents
Bone Density
Bone Diseases, Metabolic
Female
Gemfibrozil
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Male
Middle Aged
Osteogenesis
Patient Selection
Prospective Studies
Simvastatin
Treatment Outcome
Bone morphogenetic protein 2
Carboxy terminal telopeptide
Cholesterol
Fibric acid derivative
Gemfibrozil
High density lipoprotein cholesterol
Hydroxymethylglutaryl coenzyme A reductase inhibitor
Lipid
Low density lipoprotein cholesterol
Simvastatin
Triacylglycerol
Adult
Aged
Article
Blood analysis
Blood sampling
Bone density
Bone tissue
Cell differentiation
Clinical trial
Controlled clinical trial
Controlled study
Diet restriction
Drug dose increase
Female
Human
Hyperlipidemia
Lipophilicity
Major clinical study
Male
Ossification
Osteoblast
Osteoclast
Osteolysis
Osteopenia
Osteoporosis
Pleiotropy
Protein expression
Randomized controlled trial
Treatment outcome
Aged
Antilipemic Agents
Bone Density
Bone Diseases, Metabolic
Female
Gemfibrozil
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Male
Middle Aged
Osteogenesis
Patient Selection
Prospective Studies
Simvastatin
Treatment Outcome